Ajeet Gajra

Summary

Country: USA

Publications

  1. ncbi request reprint Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer
    Ajeet Gajra
    Veterans Affairs Medical Center Syracuse, NY 13210, USA
    J Clin Oncol 21:1029-34. 2003
  2. ncbi request reprint Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease
    Ajeet Gajra
    Department of Medicine, VA Medical Center, Syracuse, 800 Irving Ave, Syracuse, NY 13210, USA
    Lung Cancer 42:51-7. 2003
  3. ncbi request reprint Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma
    Ajeet Gajra
    Department of Medicine, VA Medical Center, Syracuse, New York, USA
    Am J Hematol 77:196-7. 2004
  4. ncbi request reprint Lepirudin for anticoagulation in patients with heparin-induced thrombocytopenia treated with continuous renal replacement therapy
    Ajeet Gajra
    Department of Medicine, State University of New York, Upstate Medical University, Syracuse, New York, USA
    Am J Hematol 82:391-3. 2007
  5. pmc CA125 level association with chemotherapy toxicity and functional status in older women with ovarian cancer
    Elizabeth Won
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Gynecol Cancer 23:1022-8. 2013
  6. ncbi request reprint The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer
    Ajeet Gajra
    Department of Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Lung Cancer 36:159-65. 2002
  7. ncbi request reprint Lepirudin in the management of heparin-induced thrombocytopenia
    Ajeet Gajra
    SUNY Upstate Medical University, Department of Medicine, 750 E Adams Street, CWB 275, Syracuse, NY 13210, USA
    Expert Opin Drug Metab Toxicol 4:1131-41. 2008
  8. pmc Toxicity of bevacizumab in combination with chemotherapy in older patients
    Supriya G Mohile
    University of Rochester Medical Center, Wilmot Cancer Center, Rochester, New York, USA
    Oncologist 18:408-14. 2013
  9. doi request reprint Bisphosphonate therapy is effective in the treatment of sacral giant cell tumor
    Preeti Chaudhary
    Department of Internal Medicine, SUNY Upstate Medical Center, Syracuse, NY, USA
    Onkologie 34:702-4. 2011
  10. ncbi request reprint Prolonged half-life of argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin-induced thrombocytopenia
    Uzma Athar
    Department of Medicine, SUNY Upstate Medical University, Syracuse, New York, USA
    Am J Hematol 83:245-6. 2008

Collaborators

Detail Information

Publications26

  1. ncbi request reprint Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer
    Ajeet Gajra
    Veterans Affairs Medical Center Syracuse, NY 13210, USA
    J Clin Oncol 21:1029-34. 2003
    ..We postulate that surgical sampling and pathologic evaluation of lymph nodes of surgical specimens from patients with stage I non-small-cell lung cancer (NSCLC) can have an effect on the time to recurrence and survival of these patients...
  2. ncbi request reprint Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease
    Ajeet Gajra
    Department of Medicine, VA Medical Center, Syracuse, 800 Irving Ave, Syracuse, NY 13210, USA
    Lung Cancer 42:51-7. 2003
    ..The purpose of this study was to determine the relationship between tumor size, and survival in patients with pathologic stage IA NSCLC...
  3. ncbi request reprint Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma
    Ajeet Gajra
    Department of Medicine, VA Medical Center, Syracuse, New York, USA
    Am J Hematol 77:196-7. 2004
    ..We report a patient with B-cell, follicular non-Hodgkin lymphoma and a long-standing history of myasthenia gravis and the favorable impact of rituximab on both disorders...
  4. ncbi request reprint Lepirudin for anticoagulation in patients with heparin-induced thrombocytopenia treated with continuous renal replacement therapy
    Ajeet Gajra
    Department of Medicine, State University of New York, Upstate Medical University, Syracuse, New York, USA
    Am J Hematol 82:391-3. 2007
    ..There are no guidelines in the literature regarding the management of this patient group. We report our experience with lepirudin at managing four such patients with HIT, being treated with CRRT...
  5. pmc CA125 level association with chemotherapy toxicity and functional status in older women with ovarian cancer
    Elizabeth Won
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Gynecol Cancer 23:1022-8. 2013
    ..CA125 is a sensitive biomarker for tumor burden. The study evaluates the association between CA125, geriatric assessment (GA), and treatment toxicity...
  6. ncbi request reprint The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer
    Ajeet Gajra
    Department of Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Lung Cancer 36:159-65. 2002
    ..Several studies have suggested that patients whose tumors have neuroendocrine features may be more responsive to chemotherapy. In addition, increased expression of p53 may play a role in chemotherapy resistance in patients with NSCLC...
  7. ncbi request reprint Lepirudin in the management of heparin-induced thrombocytopenia
    Ajeet Gajra
    SUNY Upstate Medical University, Department of Medicine, 750 E Adams Street, CWB 275, Syracuse, NY 13210, USA
    Expert Opin Drug Metab Toxicol 4:1131-41. 2008
    ..Lepirudin is indicated for anticoagulation in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease to prevent further thromboembolic complications...
  8. pmc Toxicity of bevacizumab in combination with chemotherapy in older patients
    Supriya G Mohile
    University of Rochester Medical Center, Wilmot Cancer Center, Rochester, New York, USA
    Oncologist 18:408-14. 2013
    ..Little is known about factors associated with receipt of bevacizumab, or whether bevacizamab is associated with increased toxicity when added to chemotherapy...
  9. doi request reprint Bisphosphonate therapy is effective in the treatment of sacral giant cell tumor
    Preeti Chaudhary
    Department of Internal Medicine, SUNY Upstate Medical Center, Syracuse, NY, USA
    Onkologie 34:702-4. 2011
    ..Sacral giant cell tumors are particularly challenging to treat as they are often quite extensive and surround the sacral nerve roots, making surgical extirpation very difficult without high morbidity and frequent local recurrence...
  10. ncbi request reprint Prolonged half-life of argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin-induced thrombocytopenia
    Uzma Athar
    Department of Medicine, SUNY Upstate Medical University, Syracuse, New York, USA
    Am J Hematol 83:245-6. 2008
    ..This case also demonstrates the lack of guidelines for the monitoring of argatroban therapy in the presence of an underlying lupus anticoagulant...
  11. doi request reprint Activation of mammalian target of rapamycin in diffuse large B-cell lymphoma: a clinicopathological study
    Neerja Vajpayee
    Department of Pathology, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Leuk Res 36:1403-9. 2012
    ..Based on our results we propose that use of targeted therapy with mTOR inhibitors, in a subset of diffuse large B-cell lymphoma patients may help improve patient survival...
  12. ncbi request reprint Thromboembolism with immunomodulatory agents in the treatment of multiple myeloma
    Anurag Singh
    SUNY Upstate Medical University, Department of Medicine, 750 E Adams Street, CWB 275, Syracuse, NY 13210, USA
    Cardiovasc Hematol Agents Med Chem 9:7-13. 2011
    ....
  13. ncbi request reprint A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer
    Chirag Shah
    Department of Medicine, SUNY Upstate Medical University, Regional Oncology Center, 750 E Adams Street, Syracuse, NY 13210, United States
    Lung Cancer 57:84-8. 2007
    ..To determine the response rate, toxicity, failure free and overall survival of weekly topotecan in patients with relapsed small cell lung cancer who received one prior platinum based chemotherapy...
  14. pmc Efficacy of vorinostat in a murine model of polycythemia vera
    Hajime Akada
    Departments of Pharmacology, State University of New York Upstate Medical University, Syracuse, 13210, USA
    Blood 119:3779-89. 2012
    ..Vorinostat treatment also decreased the mutant allele burden in mice. Our results suggest that vorinostat may have therapeutic potential for the treatment of PV and other JAK2V617F-associated myeloproliferative neoplasms...
  15. doi request reprint Treatment of advanced lung cancer in the elderly
    Ajeet Gajra
    SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Hosp Pract (1995) 39:107-15. 2011
    ..The evolving role of palliative care is discussed, as well as the need for integrating geriatric assessment in the care of elderly patients with lung cancer...
  16. ncbi request reprint Acute coronary syndrome secondary to fluorouracil infusion
    Jack I Lu
    State University of New York Upstate Medical University, Syracuse, NY, USA
    J Clin Oncol 24:2959-60. 2006
  17. pmc Use of complementary medications among older adults with cancer
    Ronald J Maggiore
    Department of Medicine, Sections of Geriatrics Palliative Medicine and Hematology Oncology, University of Chicago Medical Center, Chicago, Illinois, USA
    Cancer 118:4815-23. 2012
    ..The objective of this study was to evaluate the prevalence of complementary medication use and to identify the factors associated with its use among older adults with cancer...
  18. doi request reprint Anticoagulant-resistant thrombophilia in a patient with polycythemia vera: a case report
    Subhraleena Das
    Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, New York, USA
    Blood Coagul Fibrinolysis 22:746-8. 2011
    ..The proposed mechanisms of hypercoagulability in polycythemia vera are reviewed. To the best of our knowledge, mechanical valve thromboses as the presenting feature of polycythemia vera has not been reported previously...
  19. doi request reprint Acute leukemic appendicitis in a patient with acute promyelocytic leukemia
    Hatim Karachiwala
    Department of Medicine, SUNY Upstate Medical University Syracuse, New York, USA
    J Cancer Res Ther 8:132-4. 2012
    ..Further, this case demonstrates the need to maintain a high index of suspicion and prompt surgical intervention for surgical pathologies in neutropenic patients...
  20. doi request reprint Hypertrophic osteoarthropathy masquerading as lower extremity cellulitis and response to bisphosphonates
    Obondent Mauricio
    Department of Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    J Thorac Oncol 4:260-2. 2009
    ..We report a case with an atypical presentation of HOA. The prominent systemic signs, presentation limited to lower extremities only and an excellent response to bisphosphonates make this case unusual...
  21. doi request reprint Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases
    Neerja Vajpayee
    Division of Hematopathology, Department of Pathology, SUNY Upstate Medical University, Syracuse, NY, USA
    J Neurooncol 100:249-53. 2010
    ..To the best of our knowledge expression of STAT-3 protein in PCNSL which represents a distinct anatomical subset of ABC DLBCL with a dismal prognosis has not been studied before...
  22. ncbi request reprint Cardiovascular effects of EGFR (epidermal growth factor receptor) monoclonal antibodies
    Preeti Chaudhary
    Department of Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Cardiovasc Hematol Agents Med Chem 8:156-63. 2010
    ..As the potential clinical applications for these agents increase, clinicians using these agents need to remain vigilant regarding cardiovascular complications, especially in view of an aging cancer population...
  23. ncbi request reprint Unexplained bone marrow granulomas: is amiodarone the culprit? A report of 2 cases
    Surabhi Mukhopadhyay
    Department of Medicine, SUNY Upstate Medical University, Syracuse, New York 13210, USA
    Am J Hematol 75:110-2. 2004
    ..Amiodarone should be considered as a possible cause of bone marrow granulomas after the exclusion of other causes. Continued use of amiodarone after granuloma formation must be dictated by the underlying cardiac condition...
  24. ncbi request reprint Update on fondaparinux: role in management of thromboembolic and acute coronary events
    Tulsi Sharma
    Department of Medicine, SUNY Upstate Medical University, Syracuse, New York, NY, USA
    Cardiovasc Hematol Agents Med Chem 8:96-103. 2010
    ..In this article, we review the available literature that provides evidence for the efficacy of fondaprinux in management of thromboembolic disease as well as acute coronary syndromes...
  25. ncbi request reprint Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial
    Francis W Nugent
    Baystate Regional Cancer Program, Springfield, MA, USA
    Lung Cancer 48:267-73. 2005
    ..To assess the overall and progression-free survival, response rate, and toxicity of combined docetaxel and celecoxib in the treatment of patients with non-small cell lung cancer progressing after initial chemotherapy for advanced disease...
  26. doi request reprint Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Division of Hematology Oncology 111H, 22 South Greene Street, Baltimore, MD 21201 1595, USA
    J Clin Oncol 26:848-55. 2008
    ....